&w=3840&q=100)
Indian refiners still buying oil from Russia, report claims amid Trump's 'halt' remark
Advertisement
Indian Prime Minister Narendra Modi and Russian President Vladimir Putin. File image/ Reuters
Indian refiners have not stopped buying crude oil from Russia, news agency ANI has reported, citing sources in the government.
'Their supply decisions are guided by price, grade of crude, inventories, logistics and other economic factors,' the agency quoted the source as saying.
The sources also highlighted Russia's crucial place in the global oil market, being the world's second-largest exporter of crude.
Fears of Russian oil being pushed out of the market and the consequent dislocation of traditional trade flows drove dated Brent crude prices to soar to US$137 per barrel in March 2022.
STORY CONTINUES BELOW THIS AD
'In this challenging environment, India, as the world's third-largest energy consumer with 85 per cent crude oil import dependence, strategically adapted its sourcing to secure affordable energy while fully adhering to international norms,' said the sources.
Earlier, US President Donald Trump on Friday (August 1) said he heard that India is no longer purchasing oil from Russia. While speaking to the reporters, Trump went on to describe the alleged halting of oil purchases as a 'good step'.
'I understand India no longer is going to be buying oil from Russia,' Trump told reporters as he departed the White House for his weekend trip to his Bedminster Golf Club in New Jersey. 'That's what I heard. I don't know if that's right or not, but that's a good step. We'll see what happens,' he said.
Trump's statement came after news agency Reuters reported, citing sources, that Indian state-owned refineries suspended Russian oil purchases last week amid threats of tariffs from US and narrowing price discounts.
Meanwhile, the Ministry of External Affairs Spokesperson Randhir Jaiswal on Friday responded to the criticisms hurled by the Trump administration and defended India's longstanding partnership with Russia.
'India and Russia share a steady and time-tested partnership,' he said. Jaiswal also reaffirmed the strength of the India-US relationship, noting it is based on 'shared interests, democratic values, and robust people-to-people ties,' and expressed confidence that bilateral relations would continue to move forward despite current tensions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
18 minutes ago
- The Hindu
Another slip up by India in the trade pact with the U.K.
The India-United Kingdom Comprehensive Economic and Trade Agreement (CETA) raises several questions regarding India's commitments in the CETA's intellectual property chapter (Chapter 13). A problematic article in this chapter is Article 13.6, 'Understandings Regarding TRIPS and Public Health Measures', in particular its first paragraph: 'The Parties recognise the preferable and optimal route to promote and ensure access to medicines is through voluntary mechanisms, such as voluntary licensing which may include technology transfer on mutually agreed terms' ( India's agreeing to this provision would result in dilution of its position on two critical issues. First, India consistently backed the use of compulsory licensing as opposed to voluntary licensing, to address high prices of patented medicines. Second, India argued that advanced countries must transfer technologies to developing countries on 'favourable terms', for their industrialisation, and also for reducing their carbon footprints. EXPLAINED | What does the new U.K.-India trade deal entail? Issue of pricing High prices of patented medicines are a serious anomaly of the patent system, due to excessive rent-seeking by patentees. Compulsory licensing of patented medicines can vastly improve the affordability of high-priced medicines by facilitating the production of such medicines. This was experienced following the grant of compulsory licence to Natco Pharma in 2012 for producing an anti-cancer medicine, sorafenib tosylate. The price came down to less than ₹8,800 for a month's treatment, from the ₹2,80,428 charged by the owner of the patent on the medicine, Bayer Corporation ( For remedying such instances of excessive rent-seeking, India's law-makers included compulsory licensing as a key safeguard while amending the Patents Act to make it compatible with the World Trade Organization's (WTO) Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Both Houses of the Parliament unanimously adopted this legislation after a Joint Parliamentary Committee had carefully considered its provisions ( Also Read | India, U.K. sign trade deal, PMs launch new partnership framework Grant of compulsory licence India's TRIPS-consistent Patents Act allows grant of compulsory licence to anyone interested in producing a patented product in India, three years after the grant of a patent. This licence can be granted if: reasonable requirements of the public with respect to the patented invention are not satisfied; or the patented invention is not available to the public at reasonably affordable price, or the patented invention is not 'worked' in the territory of India, implying, it has not been commercially exploited in the country ( Patent rules monitor 'working' requirement and, accordingly, patentees must submit the working status of their inventions. They had to do so annually until this requirement was diluted through India's FTA with the European Free Trade Association, with India agreeing that the periodicity of reporting 'shall not be less than 3 years' ( This dilution, has now been reinforced through the CETA, and it takes away an important ground for issuing compulsory licences. By backing voluntary licensing to address the problem of access to medicines, India has, de facto, given up its position as a strong votary of compulsory licensing in the WTO. A coalition of developing countries, including India earned the right to issue compulsory licences through the Doha Declaration on the TRIPS Agreement and Public Health in 2001, despite strident opposition from advanced countries. The Declaration emphasised, 'each Member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted' ( Voluntary licences cannot ensure access to affordable medicines due to the weak bargaining position of domestic companies in developing countries vis-à-vis dominant pharmaceutical corporations. Médecins Sans Frontières (MSF), a medical humanitarian organisation, observed that using the terms of voluntary licences, pharmaceutical corporations can set various limitations, including to control the supply of active pharmaceutical ingredients, besides imposing restrictions on licensees. Therefore, options for getting affordable access are compromised when voluntary licences are used ( The MSF's observations were proven when Cipla produced the anti-COVID drug, remdesivir, in India under a voluntary licence from Gilead Sciences, the owner of the patent on the medicine. The price of remdesivir fixed by Cipla for India was, in purchasing power terms, higher than that Gilead had charged in the United States. COMMENT | The India-U.K. FTA spells a poor deal for public health India's demand will be affected The CETA undermines India's demand for technology transfer 'on favourable terms' in several multilateral forums. This demand was first made through the United Nations General Assembly Resolution on the New International Economic Order (NIEO) in 1974. A key aspect of the NIEO was the call for facilitated technology transfer from advanced to developing countries to promote the industrialisation efforts of the developing countries ( However, despite their best efforts, little progress was seen regarding technology transfer. The disappointment of developing countries was reflected in India's Fourth Biennial Update Report to the United Nations Framework Convention on Climate Change in 2024: 'Despite substantial national efforts and investments, barriers like slow international technology transfer and intellectual property rights (IPR) hinder the rapid adoption of [climate friendly] technologies' ( As India has compromised its long-held position that technology transfer to developing countries must be on 'favourable terms', its demand for climate-friendly technologies from advanced countries could lose its sting. Biswajit Dhar is former Professor of Economics at the Jawaharlal Nehru University. K.M. Gopakumar is Senior Researcher and Legal Adviser, Third World Network
&w=3840&q=100)
Business Standard
18 minutes ago
- Business Standard
Opec+ countries to boost oil production by 547,000 barrels per day
A group of countries that are part of the Opec+ alliance of oil-exporting countries has agreed to boost oil production, a move some believe could lower oil and gasoline prices, citing a steady global economic outlook and low oil inventories. The group met virtually on Sunday and announced that eight of its member countries would increase oil production by 547,000 barrels per day in September. The countries boosting output, including Saudi Arabia, Russia, Iraq, United Arab Emirates, Kuwait, Kazakhstan, Algeria and Oman, had been participating in voluntary production cuts, initially made in November 2023, which were scheduled to be phased out by September 2026. The announcement means the voluntary production cuts will end ahead of schedule. The move follows an Opec+ decision in July to boost production by 548,000 barrels per day in August. Opec said the production adjustments may be paused or reversed as market conditions evolve. When production increases, oil and gasoline prices may fall. But Brent crude oil, which is considered a global benchmark, has been trading near $70 per barrel, which could be due to a potential loss of Russian oil on the market and a large rise in crude inventories in China, according to research firm Clearview Energy Partners. President Trump has not obviously relented from his threat to sanction Russian energy if the Kremlin does not reach a peace deal with Ukraine as of August 7, potentially via secondary tariffs on buyers, Clearview Energy Partners said in an analyst note Sunday. The eight countries will meet again on September 7, Opec said in a news release.
Hindustan Times
18 minutes ago
- Hindustan Times
Hamas says no special food privileges for Gaza hostages
The Palestinian militant group Hamas said Sunday that Israeli hostages would not receive any "special privileges" in the food they are given compared to the rest of the Gazan population. Demonstrators take part in a protest to demand the immediate release of hostages held in Gaza since the October 7, 2023, attack on Israel by Hamas and to end the war, as a video released by Hamas of hostage Evyatar David is displayed, in Tel Aviv, Israel, August 2, 2025. REUTERS/Ammar Awad NO RESALES. NO ARCHIVES(REUTERS) "(Hamas) does not intentionally starve the captives, but they eat the same food our fighters and the general public eat. They will not receive any special privileges amid the crime of starvation and siege", Hamas's military wing, the Al-Qassam Brigades, wrote in a statement.
